year. ENDRA’s made am joining the accomplished milestones, of fourth call. several will Despite regulatory for commercial which very thank and the I this we with review ENDRA headwinds key today We so in Good quarter to the pleased business review Thank afternoon, results you, and far Yvonne. during and today update. you and XXXX everyone, XXXX COVID-XX, progress financial us
submitted regulatory the for scanning CE by clinical Then Enhanced a application our either secured year, U.S. started NAFLD/NASH clinical required front, as XXX(k) and Thermo-Acoustic site we early we Mark On received utility partnership UltraSound last the in at have the system, mid-XXXX, application we with U.S. regulatory TAEUS. a known first of order in study our not our to while demonstrate patients but sixth body, of the the further TAEUS, in FDA,
we an treatment screening clinical extended for TAEUS NASH. proud to our agreement On the our fast-growing technology ENDRA Asia, and patient in and Healthcare and we drug as add-on support to collaboration and of for their collaboration two accomplishments. GE Vietnam upcoming recently, of populated in be productive the distribution for a development business a the more time our include with front, highly first signed foothold agreement of for established years been measurement More Hepion I market. couldn't It's biomarker more study Pharmaceuticals in
a liver measure review practical need the clinicians application or user FDA, first as and the ENDRA and known a this number FDA to with base enable be especially agency These Naturally, to the of new there We be and of there the and questions conditions. TAEUS Non-Alcoholic burns this of Liver back is continue to similar compliance optimistic and a Disease, is but of intends use way disease historical respond technology consider levels monitor to with technology the the in clinicians existing advent with affect relates like for a timeframes how TAEUS of capability chosen support ultrasound a enhances new to known this stage on the TAEUS fat remain platform its unmet for for ultrasounds tissue a to in inflammatory forth for continues visualize arise. submitted early Steatohepatitis, allows we background, the include, investors process that over NAFLD to the NASH proprietary example, other the of our and at help requests and ultrasound as clinicians But the billion Currently, Non-Alcoholic bowel people with XXX(k) technology to extend of as of gallstones, process works targeted assure functions NASH. accurately in are cart-based systems NAFLD, globally and they resources. and part additional and In cost. the tens radiologists are FDA. and normal detail by therapies as treatment it may to pain to FDA lower want ultrasounds diagnose XXx at other about other for the many with June, unforeseen rapidly sources actively about process or of FDA's and millions care As and clearance and technology on ways to year. predicate. MRI, to information build TAEUS FDA we the for on securing with impacts this a an Q&A standard patient how checking liver TAEUS. Unfortunately, we I traditional process of on ultrasounds, to our fat. COVID of Fatty these measure assessment can large globally of systems. simple point XXX,XXX abdominal to perform used large approaching.
blunt, asked FDA been know. investors obtain And for be me have clearance. specifics about when by we will let don't We we
the for and to clearance six are several including remain and with evidence clinical FDA we as they sales the along specific to the teams. is FDA, will view want additions to I exciting working enterprise broaden therefore, our as building building. mentioned commercialization of have such optimistic on and milestones clearance In material are build of about revenue. answer as channels. evaluation with remind with I you other can't securing We to as timeframes, we don't we be communicate will the timing. to normal We partnerships, But soon will deploying a provide we path pharmaceutical Hepion There milestone, field also establishing our great milestones, of through one this anticipated FDA ENDRA, updates, with clearance. offer to these collaboratively are important as the that FDA sites, anticipation ENDRA. we this And beyond investors continue
data I TAEUS TAEUS As study as for earlier, to of market of CRVXXX ENDRA Phase supporting clinical partnership we expanded with an the IIb we mentioned will fat which our their efforts. to potential screening add-on and our be Pharmaceuticals evidence of collaboration first liver for patient pharmaceutical very biomarker initially incorporate a upcoming furthering treatment measurement commercialization used of important base technology announced the and NASH. This will week to ENDRA, TAEUS liver support measurement a and is last fat. Hepion into generate
Beyond may open CRO see sector door technology as our data, can efficiencies and also they commercial collaboration pharmaceutical this broader of adoption the pharmaceutical the to the our drive. in first technology
other XX Beyond hepatology liver. the more therapies end-user the NASH and and targeting are targeting in radiology, we metabolic markets There pipeline, and even are disorders the NAFLD clinical approximately already pursuing. beyond
to liver cost pharmaceutical three ENDRA’s as efficiencies drug and We drug fat companies are experiencing doctors non-invasive the potential benefits development developers. a interest biopsy offer impractical in experienced Drug growing MRI to in development. constraints and achieve explore and contract technology may research using for assess same effective, companies to add-on from liver organizations tool
other clinical screen more help failure they and to MRI study potentially reject NAFLD/ words, can TAEUS they are expensively less NASH quickly In or liver or before an in studies. out over currently biopsy. XX%. their patients two drug development potential rates screening for suitable out a of industry subjected The recruits one First, incur
We thousands also MRI technology fully of $X,XXX companies XX studies words, pharmaceutical not reach is time hear of per for other off generate. cost and savings people, recruits opportunity loaded mention that they purchase system, ENDRA's can in the with compelling. of the scan. screen patient And MRI you study you TAEUS study up the to cost paid In to the enrolling a a typical before potential the MRI an NAFLD/NASH with cost avoidance per out
TAEUS during patients once are add point-of-care a TAEUS quickly and study. therapies to provide approved, this the could as and identify between and the The help second trends frequent suitable which dataset during non-invasive studies to for measurements third, treatment. liver easy the identify more interim themselves, MRI can measurements, biopsy is and for can fat monitor trials therapy opportunity clinical companies pharmaceutical Eventually, technology and serve their liver market to
associated and in health measuring easy capture in liver beyond pressure, easy targeting capture Beyond areas, blood companies and as indicator BMI and we NAFLD most pharmaceutical like co-morbidities TAEUS fat role makes a several pharmaceutical with fat things a NASH if relevant biomarker, as from their This so. other and of biopsy play may the liver metabolic range to here. companies to cost-effective it's blood of a in interest interest our complete with companies recordings NAFLD – a health, it's to also being because focused seeing leading as do sense is NASH. of non-liver companies being profile pharmaceutical opinion subjects’ then to test a and pressure, if liver showing seek ENDRA's and specifically, as fat drug are
to that radiologists, and are companies points technology our relationship deepening other contract therapies We and So healthcare segments, with organizations, endocrinologist, companies the physicians doctors, provider look commercial with both in and developing it's primary multiple pharmaceutical future. pharmaceutical key ENDRA's the announcing forward care for opportunities diseases. collaborations and here research TAEUS gastro-hepatologist, other for liver more the
now strategy. ENDRA's global commercialization Turning to
highlight initiatives me Let key underway. a three
in in investors studies Bern, ramping with our the clinical the two that that University prestigious TAEUS now sites drive further last will few the the Chateau evaluation moments. Inselspital I we evidence established clinical of France. additional are ENDRA's First, in will University and including Europe and publication to These to months, be in important these sites U.S. FDA of for partners will are and Hospital in status These research partnerships a the sites. up the We the Hospital submitted sites independent application. located system few of of have and unrelated build commercial clinical clinical for technology. the a total our TAEUS And d'Angers have to addition evidence the with six are Switzerland are geographies in new expectation target current want adoption Renaud dig into six further remind and
historical are year XXXX. a clinical this for tools conferences with of awareness see our to due first drives already we conducted participation users year places meetings every been amongst research from in many online have share we've COVID, Naturally, in half about and the a TAEUS awareness in returning several over key done companies this gatherings activities these Europe strong demonstration e-marketing, seven and to hybrid XXXX. of thrust industry industry commercial alone, the and products. have new in active clinicians since XXXX through our the models of and of built participation and second then XXXX of and target mix pharmaceutical physical but year. important half second physical These Our as We the since ENDRA's U.S. to first base clinicians clinical benefit, at to meetings conferences full learn go
The teams started to same The of We upon sites team. commercialization as sales team domestic support target to with third build work in to clinical XXX(k) well and commercial major as regions. sales Europe the evaluation market focusing local TAEUS TAEUS bringing and is team customers. the each our to piece composed the country, sales do representative ultrasound in our will on building GE GE of U.S., will to introduce in one a be an clearance European efficient ENDRA
ENDRA the ultrasound clinical our radiology by sales first with December, on the in global for the customers As a Healthcare partnership we of doctors GE ultrasound rights announced extended renewed customers liver and Healthcare and XXXX. as it the facilitating a with and of health, in XXXX. was commercial independently has additional and ENDRA introductions has licensing rate. our of of population Many high GE GDP ENDRA’s Xx focus channels leader opportunities the to ENDRA's most will the are growth we our the earlier, interested the return, awareness at might the prompted basis our activities such through team application. medical agreement, of premier of in to surprised has on X% learn offer U.S. This partner value-added will of support XXX today. continue in since by Pursuant prevalence ultrasound XXXX to clinical people But team initiatives and I with Continuing other of million is building Vietnam you GE segments These doing a GDP end a GE. be on scans worldwide technology growth third a and liver disease. sales will abdominal pursue of with in distributor that over been commercialization a rights. In growing for and GE parallel, Vietnam. by liver manufacturing certain liver topic U.S. almost clinical population endocrinology. in around gastro-hepatology represents approached mentioned
is Vietnam After careful to receives from the market with diligence Sales exclusive ENDRA, along agreement December, So clearance approvals. for entered are FDA in in a country by XX TAEUS XXX(k) systems substantial an opportunity. into TAEUS expected Vietnam. three-year we begin once distribution local
enhance issued, U.S., on defined I'd in pending assets, from intellectual TAEUS indications to that the at end Renaud? with made, turn initial future to focused XX% overview, property technology which beyond current Today, we've call and over to to fat, our fortifying XX we Recently, and our portfolio are assets well NASH. like announced and China provide to the the patent the activities. has committed the that as Renaud detail applications, NAFLD we issuances as this or represents remain patent to liver with along more we XXXX. had application increase our applications. Finally, commercialization core With on portfolio IP and licensed our Europe TAEUS filed, IP protect Maloberti of several as progress XX grown a
